MedPath

Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

Not Applicable
Completed
Conditions
HIV Infections
Registration Number
NCT00002066
Lead Sponsor
Immunobiology Research Institute
Brief Summary

Examine the ability of thymopentin (Timunox) to:

Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Immunobiology Research Institute

🇺🇸

Annandale, New Jersey, United States

Immunobiology Research Institute
🇺🇸Annandale, New Jersey, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.